Cart (0)
Nie G et. al. (May 2023). HPV E6 promotes cell proliferation of cervical cancer cell by accelerating accumulation of RBM15 dependently of autophagy inhibition Cell Biol Int.
This study investigates the mechanism of m6A modification in HPV-related cervical cancer and reveals that HPV-E6 promotes cell proliferation by inhibiting autophagy and accelerating the accumulation of RBM15 protein, which leads to increased m6A modification on c-myc mRNA and enhanced expression of c-myc protein. These findings highlight the role of HPV-E6 in modulating cellular processes and provide insights into the molecular mechanisms underlying cervical cancer development.
(Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric))
Deng M et. al. (May 2023). METTL14 represses osteoclast formation to ameliorate osteoporosis via enhancing GPX4 mRNA stability Environ Toxicol.
This study demonstrates that METTL14, a methyltransferase-like protein, suppresses osteoclast formation and bone resorption in osteoporosis by enhancing the stability of GPX4 mRNA through m6A modification and the involvement of HuR. The findings suggest that targeting METTL14 could be a potential therapeutic approach for treating osteoporosis.
(Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric))
Chen J et. al. (May 2023). METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner Cancer Lett. 565:216222.
This study reveals that METTL3, an m6A methyltransferase, promotes pancreatic cancer cell proliferation and stemness by increasing the stability of ID2 mRNA through m6A modification, with the assistance of m6A reader protein YTHDF2. The findings suggest that targeting the METTL3-ID2 axis could be a potential therapeutic strategy for pancreatic cancer.
(Products Used: EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric), EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit)
Liu J et. al. (May 2023). N6-methyladenosine helps Apostichopus japonicus resist Vibrio splendidus infection by targeting coelomocyte autophagy via the AjULK-AjYTHDF/AjEEF-1α axis Commun Biol. 6(1):547.
This study investigates the role of N6-methyladenosine (m6A) modification in autophagy regulation during Vibrio splendidus infection in Apostichopus japonicus. The findings demonstrate that m6A modification, mediated by AjMETTL3 and recognized by AjYTHDF, promotes coelomocyte autophagy via the AjULK-AjYTHDF/AjEEF-1α axis, thereby helping A. japonicus resist V. splendidus infection.
(Products Used: EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit)
Lei C et. al. (May 2023). Hypericin Ameliorates Depression-like Behaviors via Neurotrophin Signaling Pathway Mediating m6A Epitranscriptome Modification Molecules. 28(9)
This study investigates the antidepressant effects of hypericin, a compound found in St. John's wort, and its relationship to N6-methyladenosine (m6A) mRNA modification. The findings demonstrate that hypericin ameliorates depressive-like behavior in a mouse model of depression by upregulating m6A-modifying enzymes METTL3 and WTAP, leading to m6A modifications in genes related to the neurotrophin signaling pathway, suggesting that m6A modifications and the neurotrophin signaling pathway may be involved in the pathogenesis of depression and the efficacy of antidepressants.
(Products Used: EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit)
Aobulikasimu A et. al. (May 2023). SIRT6-PAI-1 axis is a promising therapeutic target in aging-related bone metabolic disruption Sci Rep. 13(1):7991.
The study investigated the role of SIRT6, a longevity-associated factor, in osteocytes and its impact on bone metabolism in aged animals. The findings suggest that targeting the SIRT6-PAI-1 axis may hold promise as a therapeutic approach for addressing age-related bone metabolic disruptions, as demonstrated by the reversal of osteopenia and improved bone mass and serum phosphate levels in mice lacking PAI-1.
(Products Used: EpiQuik Chromatin Immunoprecipitation (ChIP) Kit)
Li Y et. al. (August 2023). TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses J Exp Med. 220(8)
The article investigates the role of the TRAF3-EWSR1 signaling axis in regulating germinal center (GC) responses, which are crucial for humoral immunity. The study reveals that EWSR1 acts as a brake on constitutive GC generation and antibody production, while TRAF3 serves as a negative regulator of EWSR1, highlighting the potential of targeting this signaling axis as a therapeutic approach to modulate GC responses and enhance humoral immunity in infectious diseases.
(Products Used: EpiQuik Plant ChIP Kit)
Eleazer R et. al. (April 2023). PARP1 Regulates Circular RNA Biogenesis though Control of Transcriptional Dynamics Cells. 12(8)
This article investigates the role of PARP1 in regulating circular RNA (circRNA) biogenesis. The results reveal that PARP1 influences circRNA production by modulating transcriptional kinetics through its interaction with RNA polymerase II (RNAPII) and its effect on gene architecture, providing insights into the regulatory mechanisms of circRNA formation and gene function.
(Products Used: Histone Acetyl H3K14ac Peptide)
Liu L et. al. (April 2023). TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner Cancers (Basel). 15(9)
In this study, the researchers explore the regulatory mechanisms of protein arginine methyltransferase 5 (PRMT5), an enzyme involved in multiple cellular processes and frequently implicated in cancer. Their findings demonstrate that TRAF6 acts as an upstream E3 ubiquitin ligase, promoting PRMT5 ubiquitination and activation. This discovery enhances our understanding of the intricate regulatory pathways governing PRMT5 function and may have implications for developing therapeutic interventions targeting PRMT5 in cancer.
(Products Used: Histone H4R3 Dimethyl Symmetric (H4R3me2s) Polyclonal Antibody)
Zhu X et. al. (May 2023). The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage J Neuroinflammation. 20(1):119.
In this study, the effects of the BET PROTAC inhibitor dBET6 on light-induced retinal degeneration and its mechanism of action were investigated. The findings demonstrate that dBET6 treatment improves retinal function, suppresses retinal inflammation, and inhibits the activation of the cGAS-STING pathway in reactive retinal macrophages/microglia, suggesting its potential as a therapeutic strategy for retinal degenerative diseases.
(Products Used: EpiSonic 2000 Sonication System)
